Baseline apparent diffusion coefficient as a predictor of response to liver-directed therapies in hepatocellular carcinoma

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Predicting outcomes in patients with hepatocellular carcinoma (HCC) who undergo locoregional therapies remains a substantial clinical challenge. The purpose of this study was to investigate pre-procedure diffusion weighted magnetic resonance imaging (DW-MRI) as an imaging biomarker for tumoral response to therapy for patients with HCC undergoing drug eluting embolic (DEE) chemoembolization and radioembolization. A retrospective review of HCC patients who underwent DEE chemoembolization or radioembolization was performed. Of the 58 patients who comprised the study population, 32 underwent DEE chemoembolization and 26 underwent radioembolization. There was no significant difference in median apparent diffusion coefficient (ADC) values across the two treatment groups (1.01 × 10−3 mm2/s, P = 0.25). The immediate objective response (OR) rate was 71% (40/56). Tumors with high ADC values were found to have a higher probability of OR within 90 days (odds ratio 4.4, P = 0.03). Moreover, index lesion specific progression free survival (PFS) was greater for high ADC tumors, independent of conventional predictors of treatment response (hazard ratio 0.44, P = 0.01). Low ADC was associated with poorer PFS (P = 0.02). Pre-procedure ADC < 1.01 × 10−3 mm2/s is an independent predictor of poorer immediate OR and index lesion specific PFS in patients with HCC undergoing DEE chemoembolization or radioembolization.

Original languageEnglish (US)
Article number83
JournalJournal of Clinical Medicine
Volume7
Issue number4
DOIs
StatePublished - Apr 14 2018

Keywords

  • Chemoembolization
  • Diffusion weighted imaging
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Baseline apparent diffusion coefficient as a predictor of response to liver-directed therapies in hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this